Previous 10 | Next 10 |
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced voting results for its annual general meeting (the “Meeting”) of shareholders held on May 17, 2023. Shareholders re-elected six of eight incumbent directors to th...
2023-05-11 14:02:17 ET The largest shareholder of Aurinia Pharmaceuticals ( NASDAQ: AUPH ) said it plans to withholder support for seven board members at the company's upcoming annual meeting. Iljin SNT, which has a 6.1% stake, said it plans to withhold support from seven board ...
First study to assess histologic changes in the kidneys of patients with lupus nephritis treated with LUPKYNIS ® (voclosporin) Treatment was not associated with chronic injury, with the average chronicity index remaining stable in both treatment arms from baseline to follow-up ...
2023-05-04 13:08:04 ET Start Time: 08:30 End Time: 09:27 Aurinia Pharmaceuticals Inc. (AUPH) Q1 2023 Earnings Conference Call May 04, 2023, 08:30 AM ET Company Participants Peter Greenleaf - President and CEO Joe Miller - CFO Jamie Harrell - Head of IR ...
2023-05-04 07:48:27 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) shares spiked in the pre-market Thursday after the Canadian biotech posted a strong revenue beat with its Q1 2023 financials and increased its outlook for 2023 amid a strong uptake for its lupus nephritis therapy Lupkyn...
2023-05-04 06:03:45 ET Aurinia Pharma press release ( NASDAQ: AUPH ): Q1 GAAP EPS of -$0.18 beats by $0.04 . Revenue of $34.41M (+59.1% Y/Y) beats by $6.29M . As of March 31, 2023, Aurinia had cash, cash equivalents and restricted cash and short-term investment...
$34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year Increases 2023 revenue guidance range to $135 - $155 million from net product sales of LUPKYNIS Significant progress across Commercial, R&D and Intellectual ...
2023-05-03 15:01:12 ET Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open. The consensus EPS Estimate is -$0.22 and the consensus Revenue Estimate is $28.12M (+30.0% Y/Y). Over the last 3 months, EPS es...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS ® (voclosporin) as an option for treating adults with active lupus nephritis (LN) class III, IV or V (including ...
2023-05-03 03:10:35 ET Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021 the Company introduced the first FDA-approved oral therapy...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...
2024-06-27 04:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four...